| zurück Home | CD 38 | ||||
| allgemeines | An der Abstoßung transplantierten Nieren beteiligt. | ||||
| Biochemie | transmembranes Glycoprotein(5) | ||||
| Expression | Monocyten, CLL, Plasmoblasten, kurzlebige und langlebige Plasmazellen, aktivierte T-Zellen, B-Zellen, NK, Neutrophile, myeloide Zellen | ||||
| CLL | CD38-Expression: ungünstige Prognose | ||||
| CD38-MAB | Daratumumab | Plasmozytom | Darzalex® | ||
| CM313 | ITP | ||||
| Felzartamab | Nierentransplantation (4) | ||||
| Quellen |
1.) Agarbati S, Benfaremo D, Viola N, et al.: Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis. Front Immunol 2022; 13: 1072462. 2.) Morra M, Zubiaur M, Terhorst C, Sancho J, Malavasi F: CD38 is functionally dependent on the TCR/CD3 complex in human T cells. FASEB J 1998; 12: 581-92. 3.) Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M: CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol 2020; 11: 597959. 4.) Mayer K A, et al.: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med 2024;391:122-32. DOI: 10.1056/NEJMoa2400763 5.) Horenstein AL, Faini AC, Morandi F, et al.: The circular life of human CD38: from basic science to clinics and back. Molecules 2020; 25: 4844. | ||||
Teil von |
CD (Immunologie) | CD (Onkologie) | Immunologie: Wirkstoffe und Rezeptoren | Immunologie | Blut, Knochenmark |
|
| |||||
Impressum Zuletzt geändert am 28.07.2024 19:39